Logo

Pacific Biometrics Snags Two Clinical Biomarker Research Contracts

Apr 07, 2008
NEW YORK (GenomeWeb News) – Pacific Biometrics said today that it has been awarded two contracts worth a total of $1.6 million from an unnamed company to provide clinical services for use in rheumatoid arthritis drug development programs.
 
The Seattle-based firm said the contracts are part of a series of four contracts related to a global development program. PBI will offer testing for a panel of inflammatory, metabolic, cardiovascular, and musculoskeletal biomarkers to support its partner’s phase III clinical program.
 
PBI CEO Ron Helm said the agreements should “have a meaningful impact” on the company’s financials in 2009, 2010, and in 2011.
 
Helm also said that the drug in question “may have applicability to a broader range of inflammatory diseases” beyond rheumatoid arthritis.
 
Further financial terms of the agreements were not released.

Breaking News
The Scan

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.

Seagull Microbiome Altered by Microplastic Exposure

The overall diversity and the composition at gut microbiome sites appear to coincide with microplastic exposure and ingestion in two wild bird species, according to a new Nature Ecology and Evolution study.